This four-part educational series highlights key trends emerging in China biopharmaceuticals, using select content from BioPlan Associates’ 2018 report on the biopharmaceutical industry in China.
In the next few years, our industry is likely to see more applications of robotic systems, particularly mobile and collaborative robots in warehouse and production floors of biomanufacturing facilities.
Cell and gene therapy development presents significant data challenges. This article presents a CFR Part 11 compliant data management system project that Skyland Analytics and bluebird bio have undertaken.
Horizon’s GS-KO CHO SOURCE cell line is available with an unlimited use license, and the company allows for and actively encourages cell-line modifications to improve biomanufacturing performance.